These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 156765)
21. Cell-mediated immunity to Moloney sarcoma virus in mice. II. Analysis of antigenic specificities involved in T lymphocyte-mediated in vivo rejection of murine sarcoma virus-induced tumors. Gorczynski RM; Knight RA Eur J Immunol; 1975 Feb; 5(2):148-55. PubMed ID: 1086221 [TBL] [Abstract][Full Text] [Related]
22. Functional activity in vivo of effector T cell populations. II. Anti-tumor activity exhibited by syngeneic anti-MoMULV-specific cytolytic T cell clones. Engers HD; Lahaye T; Sorenson GD; Glasebrook AL; Horvath C; Brunner KT J Immunol; 1984 Sep; 133(3):1664-70. PubMed ID: 6205090 [TBL] [Abstract][Full Text] [Related]
23. T cell-mediated immunity to oncornavirus-induced tumors. II. Ability of different T cell sets to prevent tumor growth in vivo. Leclerc JC; Cantor H J Immunol; 1980 Feb; 124(2):851-4. PubMed ID: 6243333 [TBL] [Abstract][Full Text] [Related]
24. Characterization to effector lymphocytes associated with immunity to murine sarcoma virus (MSV)-induced tumors. II. Repeated stimulation and proliferation in vitro of specific cytolytic T lymphocytes. Plata F; Jongeneel CV J Immunol; 1977 Aug; 119(2):623-9. PubMed ID: 196025 [No Abstract] [Full Text] [Related]
25. Generation of cytotoxic T lymphocytes in vitro. VI. Effect of cell density on response in mixed leukocyte cultures. Fitch FW; Engers HD; MacDonald HR; Cerottini JC; Brunner KT J Immunol; 1975 Dec; 115(6):1688-94. PubMed ID: 127012 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of cytolytic T lymphocyte clones reactive with Moloney leukemia virus-associated antigens by monoclonal antibodies: a direct approach to the study of H-2 restriction. Weiss A; MacDonald HR; Cerottini JC; Brunner KT J Immunol; 1981 Feb; 126(2):482-5. PubMed ID: 6450244 [TBL] [Abstract][Full Text] [Related]
27. Retrovirus-induced changes in major histocompatibility complex antigen expression influence susceptibility to lysis by cytotoxic T lymphocytes. Flyer DC; Burakoff SJ; Faller DV J Immunol; 1985 Oct; 135(4):2287-92. PubMed ID: 2411792 [TBL] [Abstract][Full Text] [Related]
28. Selective failure of accessory cell function in Moloney murine leukemia virus-tolerant mice. Biasi G; Collavo D; Chieco-Bianchi L J Immunol; 1983 Jul; 131(1):16-8. PubMed ID: 6223070 [TBL] [Abstract][Full Text] [Related]
29. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1. Inge TH; Hoover SK; Susskind BM; Barrett SK; Bear HD Cancer Res; 1992 Mar; 52(6):1386-92. PubMed ID: 1531782 [TBL] [Abstract][Full Text] [Related]
30. Accessory cells in the in vitro generation of type C virus-specific T killer lymphocytes. II. Demonstration of a T helper cell in the spleen of in vivo primed mice. Gomard E; Wybier-Franqui J; Simmler MC; McKenzie IF; Levy JP J Immunol; 1981 Dec; 127(6):2291-5. PubMed ID: 6170695 [TBL] [Abstract][Full Text] [Related]
31. Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens. Bear HD Cancer Res; 1986 Apr; 46(4 Pt 1):1805-12. PubMed ID: 2936451 [TBL] [Abstract][Full Text] [Related]
32. Distinct proliferative T cell clonotypes are generated in response to a murine retrovirus-induced syngeneic T cell leukemia: viral gp70 antigen-specific MT4+ clones and Lyt-2+ cytolytic clones which recognize a tumor-specific cell surface antigen. Matis LA; Ruscetti SK; Longo DL; Jacobson S; Brown EJ; Zinn S; Kruisbeek AM J Immunol; 1985 Jul; 135(1):703-13. PubMed ID: 2582053 [TBL] [Abstract][Full Text] [Related]
34. Flow-microfluorometric monitoring of oligoclonal CD8+ T cell responses to an immunodominant Moloney leukemia virus-encoded epitope in vivo. Brawand P; Biasi G; Horvath C; Cerottini JC; MacDonald HR J Immunol; 1998 Feb; 160(4):1659-65. PubMed ID: 9469422 [TBL] [Abstract][Full Text] [Related]
35. Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response. Von Hoegen P; Weber E; Schirrmacher V Eur J Immunol; 1988 Aug; 18(8):1159-66. PubMed ID: 2970967 [TBL] [Abstract][Full Text] [Related]
37. Limiting dilution analysis of alloantigen-reactive T lymphocytes. IV. High frequency of cytolytic T lymphocyte precursor cells in MLC blasts separated by velocity sedimentation. Maryanski JL; MacDonald HR; Cerottini JC J Immunol; 1980 Jan; 124(1):42-7. PubMed ID: 6444230 [TBL] [Abstract][Full Text] [Related]
38. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma. Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908 [TBL] [Abstract][Full Text] [Related]
39. Tumor inhibiting capacity of spleen and lymph node cells from mice with murine sarcoma virus (MSV-M)-induced tumors. Weiland E; Mussgay M Z Immunitatsforsch Exp Klin Immunol; 1975 Nov; 150(5):414-23. PubMed ID: 181922 [TBL] [Abstract][Full Text] [Related]
40. The immunological basis of tumor rejection: the absolute dependence of the effector arm on sensitized T cells after chemoimmunotherapy of a murine sarcoma. Evans R; Duffy T J Immunol; 1985 Jun; 134(6):4255-60. PubMed ID: 3872913 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]